Akribion Therapeutics

Akribion Therapeutics is a biotechnology company operator that plans to develop RNA-guided, nuclease-based programmable cell depletion technology. The company’s gene-editing platform can kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and the intracellular RNA sequence, ensuring that only target cells are affected while healthy cells remain unharmed. This allows healthcare professionals to quickly adapt the platform to target different cells, significantly accelerating the development of new therapies compared to traditional methods.